Suppr超能文献

继续阿司匹林治疗可能是胃内镜黏膜下剥离术下肝素替代治疗后延迟出血的危险因素:一项回顾性多中心研究。

Continued Aspirin Treatment May Be a Risk Factor of Delayed Bleeding after Gastric Endoscopic Submucosal Dissection under Heparin Replacement: A Retrospective Multicenter Study.

机构信息

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.

Department of Gastroenterology, Japanese Red Cross Okayama Hospital, Japan.

出版信息

Intern Med. 2020 Nov 1;59(21):2643-2651. doi: 10.2169/internalmedicine.4998-20. Epub 2020 Jul 7.

Abstract

Objective Gastric endoscopic submucosal dissection (ESD) under heparin replacement (HR) of warfarin reportedly has a high risk of delayed bleeding (24-57%). It is possible that the delayed bleeding risk may have changed over the years. We evaluated the current risk of delayed bleeding after gastric ESD under HR of anticoagulant agents. Methods We retrospectively reviewed the delayed bleeding rate and analyzed the risk factors for delayed bleeding. Patients Consecutive patients who underwent gastric ESD under HR of anticoagulant agents from July 2015 to June 2017. Results A total of 32 patients with a solitary early gastric cancer and taking anticoagulant agents were analyzed, including 24 patients on warfarin (the warfarin group) and 8 patients on direct oral anticoagulants (the DOAC group). Three (9.4%) patients experienced delayed bleeding: three (12.5%) patients in the warfarin group and no patients in the DOAC group. Continued aspirin treatment was identified to be a risk factor of delayed bleeding (p=0.01). Conclusion Careful management may be required for patients undergoing gastric ESD under continued aspirin treatment in addition to HR of anticoagulant agents; although the delayed bleeding risk after gastric ESD under HR of anticoagulant agents might have decreased over the years.

摘要

目的 据报道,在华法林替代(HR)的情况下进行胃内镜黏膜下剥离术(ESD),延迟性出血(24-57%)的风险较高。这种延迟性出血的风险可能随着时间的推移而发生变化。我们评估了在抗凝药物 HR 下进行胃 ESD 后延迟性出血的当前风险。

方法 我们回顾性地回顾了延迟性出血的发生率,并分析了延迟性出血的危险因素。

患者 连续接受抗凝药物 HR 下胃 ESD 的患者,纳入时间为 2015 年 7 月至 2017 年 6 月。

结果 共分析了 32 例接受抗凝药物 HR 下的单发早期胃癌患者,包括 24 例华法林患者(华法林组)和 8 例直接口服抗凝剂患者(DOAC 组)。3(9.4%)例患者发生延迟性出血:华法林组 3(12.5%)例,DOAC 组无患者。持续使用阿司匹林被认为是延迟性出血的危险因素(p=0.01)。

结论 除了 HR 抗凝剂外,对于正在接受阿司匹林治疗的患者进行胃 ESD 可能需要谨慎管理;尽管近年来抗凝药物 HR 下胃 ESD 后延迟性出血的风险可能已经降低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/518f/7691037/e1e65f62330d/1349-7235-59-2643-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验